Is This Drug Enough To Revive Hope in Eli Lilly's Pipeline?

Eli Lilly struggles to gain approval and regain diabetes market share.

Mar 4, 2014 at 2:30PM

Eli Lilly & Co (NYSE:LLY) snagged a win (or at least avoided a loss) this week, announcing that its projected blockbuster GLP-1 agonist diabetes medication dulaglutide was comparable to current lead treatment Victoza (liraglutide) by Novo Nordisk (NYSE:NVO).

Non-inferiority?
The fanfare surrounding this 'non-inferiority' isn't necessarily inflated. This is the first time any GLP-1 has measured up to Victoza, measured by HbA1c levels over 26 weeks. This is an indicator of the average blood sugar levels in patients from the prior 90 days, and Lilly already proved superiority, not just non-inferiority, to AstraZeneca's (NYSE:AZN) Byetta (exenatide), Merck's (NYSE:MRK) Januvia and first-line diabetes treatment metformin.

It should be noted that Lilly's dosing would be once weekly as opposed to once daily and may gain some clinical benefit in patient compliance as a result of that easier regimen. Otherwise, however, dulaglutide and Victoza really are quite equitable. Side effects were similar, with gastrointestinal effects most common. Phase II studies have shown a weight-loss effect in patients, but Victoza and other GLP-1 drugs have similar benefits.

Full data from this trial (AWARD-6) were not released, but are expected to be presented later this year in addition to data from AWARD-2 (dulaglutide vs. insulin glargine) and AWARD-4 (dulaglutide+insulin lispro v. insulin glargine + insulin lispro ). AWARD-6 examined dulaglutide v. the maximum dosage of Victoza in 599 patients currently taking metformin.

Dulaglutide has already been submitted for marketing approval with both the FDA and EMA, and the company's medical director has projected approval this year. If approved, this would be a major victory for Lilly, following several pipeline failures for Alzheimer's disease (solanezumab), schizophrenia (pomaglumetad methionil) and rheumatoid arthritis.

About those competitors
Dulaglutide would be the first approved once-weekly and 'ready to use' GLP-1 agonist, and analysts project sales of dulaglutide to be anywhere from $700 million to $2 billion. Meanwhile, Eli Lilly continues to develop empagliflozin, an SGLT2 diabetes treatment, although it will likely lag dulaglutide's approval.

Interestingly, twice-a-day Byetta, also a GLP-1 agonist, was originally Eli Lilly's product with partner Amylin. When the two companies broke up, Amylin and Byetta were sold to Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca (NYSE:AZN ); Bristol-Myers since sold its stake in diabetes to AstraZeneca.

Exenatide, the chemical name of Byetta, is also marketed as once-weekly dosing Bydureon by AstraZeneca. Bydureon is the only once-weekly GLP-1 agonist currently marketed, but Eli Lilly was careful to call dulaglutide 'ready to use', offering a direct contrast to the need for pre-mixing Bydureon prior to injecting it with a large needle.

The flurry of activity surrounding ownership of Amylin and Byetta/Bydureon set back sales of Bydureon, and now the positive results coming from Eli Lilly's dulaglutide may present significant competition to AstraZeneca as well. AstraZeneca is looking at a pen-delivery system that would solve both problems of pre-mixing and the large bore needle necessary for injection.

Looking at diabetes share, Eli Lilly is staunchly secure at least historically in the market as being the first to mass-produce insulin. Humalog is still a major product for Lilly, and AstraZeneca certainly suffers from not having any insulin product in its repertoire. However, Novo Nordisk is the behemoth to beat (or aspire to) when it comes to diabetes.

Novo Nordisk's Victoza currently owns about 70% of the GLP-1 market with sales on target to beat $2 billion this year. The Danish drug company comes from a position of superiority over the struggling Eli Lilly, particularly having recently reported fourth quarter earnings well above estimates. The company is most dominant in diabetes, although it also has reach in both hematology and other hormones, nabbing an approval for NovoEight last year for hemophilia and filing with the FDA and EMA last December for use of liraglutide in obesity.

Bottom line
Diabetes could be Eli Lilly's saving grace, and the company's historic presence in the field is on its side. 'Non-inferiority' to Victoza is perhaps not exciting investors as much as executives would like, as shares only received a slight bump with the announcement. However, it would nonetheless be an improvement over the dry spell inapprovals. And an approval is more important than anything to prove CEO John Lechleiter's strategy to continue focusing on R&D rather than the dealmaking and buyouts others in Big Pharma have turned to.

Lilly, besides having to prove itself by R&D, has been struggling from patent expirations such as its antidepressant Cymbalta and antipsychotic Zyprexa, but it has been having some positive news as of late. Fourth quarter sales were better than expected given the generic competition against Cymbalta, buffered by price increases in some of its other prescription drugs. From the R&D front, the company also released positive data in lung cancer for its blockbuster hopeful ramucirumab, an agent with weak success in stomach cancer but phase III failure for breast cancer.

Lilly hopes to secure approval for dulaglutide, empagliflozin and ramucirumab this year, but it is dulaglutide that leads the bunch on likelihood and projected peak sales. It is uncertain if non-inferiority is good enough to revive Lilly from its dry spell, but there is some solid potential.

Potentially stronger dividend stocks
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it’s true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor’s portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Potentially stronger dividend stocks
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it’s true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor’s portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Amy Ho has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers